Merck
CN
  • In vivo evidence for the resistance of Theileria annulata to buparvaquone.

In vivo evidence for the resistance of Theileria annulata to buparvaquone.

Veterinary parasitology (2010-02-27)
Moez Mhadhbi, Abdelkarim Naouach, Aïssa Boumiza, Mohamed Faouzi Chaabani, Souha BenAbderazzak, Mohamed Aziz Darghouth
ABSTRACT

The present study describes an outbreak of tropical theileriosis cases refractory to buparvaquone treatment, which occurred in a small-size dairy farm in Tunisia. Out of seven treated cows, four died in spite of repeated buparvaquone injections (2.5 and 5 mg kg(-1)) and the monitoring of the affected cows showed no improvement of the course of the disease with a consistent decrease in the haematocrit, the persistence of fever and an increased parasitaemia after treatment. Ticks were fed on a calf experimentally infected with one isolate established in culture from one of the cases and the resultant infected ticks ground up to generate a supernatant infected with the potentially resistant stock. This was used to experimentally infect three calves, and the clinical observations, post-buparvaquone treatment, showed an absence of the usual effect of buparvaquone treatment on the parasite Theileria annulata, such as the rapid decline of schizont index and parasitaemia and a rapid recovery from the disease. These results confirmed for the first time the occurrence of resistance to buparvaquone in the protozoan T. annulata.

MATERIALS
Product Number
Brand
Product Description

Supelco
Buparvaquone, VETRANAL®, analytical standard